Previous studies of the CRC cases have noted that mutations impairing or eliminating the function of PTEN co-occur with mutations in KRAS, PIK3CA, and SMAD4, but tend to be mutually exclusive with those inactivating TP5355,56. This evidence concerns the gene KRAS and colorectal carcinoma.